First targeted alpha therapy receives breakthrough designation
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to AlphaMedix (212Pb-DOTAMTATE) for the treatment of adult patients with unresectable or metastatic, progressive somatostatin receptor expressing gastroenteropancreatic neuroendocrine tumours (GEP-NETs) who are naïve to peptide receptor radionuclide therapy (PRRT). AlphaMedix is a targeted alpha therapy currently in… Read More
